HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer
Тип публикации: Journal Article
Дата публикации: 2020-06-01
scimago Q1
wos Q2
БС1
SJR: 1.187
CiteScore: 6.2
Impact factor: 3.2
ISSN: 15330028, 19380674
PubMed ID:
32229076
Oncology
Gastroenterology
Краткое описание
The prognosis of metastatic colorectal cancer (mCRC) is poor. Cetuximab and panitumumab, 2 anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs), improve the overall survival of patients with RAS wild-type mCRC. However, not all patients with RAS wild-type mCRC will respond to anti-EGFR mAbs. Several retrospective trials suggest that human epidermal growth factor receptor 2 (HER2) amplification could be a predictive biomarker of resistance to anti-EGFR mAbs in patients with metastatic RAS and RAF wild-type mCRC. Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC. Although these findings need to be confirmed in randomized trials, the data strongly support that HER2 is an actionable gene in CRC and provide the scientific rationale to test HER2 status on a routine basis in this disease. In this review, we discuss the predictive value of HER2 activation in CRC as well as its potential role as a treatment target.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
1
2
|
|
|
International Journal of Molecular Sciences
2 публикации, 4.76%
|
|
|
Almanac of Clinical Medicine
2 публикации, 4.76%
|
|
|
Biomarkers in Medicine
1 публикация, 2.38%
|
|
|
Current Opinion in Oncology
1 публикация, 2.38%
|
|
|
World Journal of Gastrointestinal Oncology
1 публикация, 2.38%
|
|
|
Frontiers in Immunology
1 публикация, 2.38%
|
|
|
Journal of Clinical Medicine
1 публикация, 2.38%
|
|
|
International Journal of Colorectal Disease
1 публикация, 2.38%
|
|
|
Cancer
1 публикация, 2.38%
|
|
|
Critical Reviews in Oncology/Hematology
1 публикация, 2.38%
|
|
|
Journal of Cellular and Molecular Medicine
1 публикация, 2.38%
|
|
|
Chemical Biology and Drug Design
1 публикация, 2.38%
|
|
|
Molecular Pharmaceutics
1 публикация, 2.38%
|
|
|
Cancer Management and Research
1 публикация, 2.38%
|
|
|
Expert Opinion on Pharmacotherapy
1 публикация, 2.38%
|
|
|
Expert Opinion on Investigational Drugs
1 публикация, 2.38%
|
|
|
Cureus
1 публикация, 2.38%
|
|
|
Cancer Medicine
1 публикация, 2.38%
|
|
|
Journal of Gastrointestinal Oncology
1 публикация, 2.38%
|
|
|
Cancer Causes and Control
1 публикация, 2.38%
|
|
|
Biochimica et Biophysica Acta - Molecular Basis of Disease
1 публикация, 2.38%
|
|
|
Biomedicines
1 публикация, 2.38%
|
|
|
Frontiers in Oncology
1 публикация, 2.38%
|
|
|
Gene
1 публикация, 2.38%
|
|
|
Scientific Reports
1 публикация, 2.38%
|
|
|
Bioorganic Chemistry
1 публикация, 2.38%
|
|
|
Molecular Biology Reports
1 публикация, 2.38%
|
|
|
Journal of Personalized Medicine
1 публикация, 2.38%
|
|
|
Annals of Diagnostic Pathology
1 публикация, 2.38%
|
|
|
1
2
|
Издатели
|
1
2
3
4
5
6
7
8
|
|
|
Elsevier
8 публикаций, 19.05%
|
|
|
Springer Nature
7 публикаций, 16.67%
|
|
|
MDPI
5 публикаций, 11.9%
|
|
|
Taylor & Francis
4 публикации, 9.52%
|
|
|
Wiley
4 публикации, 9.52%
|
|
|
Frontiers Media S.A.
2 публикации, 4.76%
|
|
|
Moscow Regional Research and Clinical Institute (MONIKI)
2 публикации, 4.76%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 публикация, 2.38%
|
|
|
Baishideng Publishing Group
1 публикация, 2.38%
|
|
|
American Chemical Society (ACS)
1 публикация, 2.38%
|
|
|
AME Publishing Company
1 публикация, 2.38%
|
|
|
JMIR Publications
1 публикация, 2.38%
|
|
|
Media Sphere Publishing House
1 публикация, 2.38%
|
|
|
Cold Spring Harbor Laboratory
1 публикация, 2.38%
|
|
|
Society for Translational Oncology
1 публикация, 2.38%
|
|
|
1
2
3
4
5
6
7
8
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
42
Всего цитирований:
42
Цитирований c 2024:
12
(28.57%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
De Cuyper A., Van den Eynde M., Machiels J. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer // Clinical Colorectal Cancer. 2020. Vol. 19. No. 2. pp. 65-72.
ГОСТ со всеми авторами (до 50)
Скопировать
De Cuyper A., Van den Eynde M., Machiels J. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer // Clinical Colorectal Cancer. 2020. Vol. 19. No. 2. pp. 65-72.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1016/j.clcc.2020.02.007
UR - https://doi.org/10.1016/j.clcc.2020.02.007
TI - HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer
T2 - Clinical Colorectal Cancer
AU - De Cuyper, Astrid
AU - Van den Eynde, Marc
AU - Machiels, Jean-Pascal
PY - 2020
DA - 2020/06/01
PB - Elsevier
SP - 65-72
IS - 2
VL - 19
PMID - 32229076
SN - 1533-0028
SN - 1938-0674
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2020_De Cuyper,
author = {Astrid De Cuyper and Marc Van den Eynde and Jean-Pascal Machiels},
title = {HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer},
journal = {Clinical Colorectal Cancer},
year = {2020},
volume = {19},
publisher = {Elsevier},
month = {jun},
url = {https://doi.org/10.1016/j.clcc.2020.02.007},
number = {2},
pages = {65--72},
doi = {10.1016/j.clcc.2020.02.007}
}
Цитировать
MLA
Скопировать
De Cuyper, Astrid, et al. “HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.” Clinical Colorectal Cancer, vol. 19, no. 2, Jun. 2020, pp. 65-72. https://doi.org/10.1016/j.clcc.2020.02.007.